In this issue:
Extending trastuzumab from 1 to 2 years: no additional benefit
Adding bevacizumab to adjuvant chemotherapy in TNBC
Premenopausal breast cancer: higher BMI linked to poorer outcomes
Letrozole vs anastrozole: similar efficacy, toxicity profiles
Outcomes of BRAF-mutant advanced CRC with chemotherapy
Considering cetuximab in treatment of metastatic CRC
Neoadjuvant therapy in rectal cancer
Adding pravastatin to chemotherapy: no benefit in SCLC
Erlotinib vs gefitinib in EGFR-mutant advanced NSCLC
First-line ceritinib active in advanced ALK-rearranged NSCLC
Please login below to download this issue (PDF)